Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients (156 views)
Biotechnol Genet Eng Rev (ISSN: 0264-8725linking), 2023; N/D: 1-14.
Export to BibTeX Export to EndNote
Paper type: Journal Article , Review
Impact factor: 0, 5-year impact factor: 0
Url: Not available.
Keywords: Checkpoint Inhibitors , Median Progression Free Survival , Metastasize , Metastatic Melanoma , Nivolumab
Affiliations:
*** IBB - CNR ***
Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia.
Medical Laboratory Technology Department, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia.
Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
King Fahd Medical Research Center, and Yousef Abdullatif Jameel Chair of Prophetic Medicine Application, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
School of Life Sciences, Manipal Academy of Higher Education, Dubai, United Arab Emirates.
Institute of Biostructure and Bioimaging (CNR), Molecular Biotechnology Center, Turin, Italy.
Unit of Gastroenterology, Molinette Hospital, Turin, Italy.
References:
Not available.
Biotechnol Genet Eng Rev (ISSN: 0264-8725linking), 2023; N/D: 1-14.
Export to BibTeX Export to EndNote
Paper type: Journal Article , Review
Impact factor: 0, 5-year impact factor: 0
Url: Not available.
Keywords: Checkpoint Inhibitors , Median Progression Free Survival , Metastasize , Metastatic Melanoma , Nivolumab
Affiliations:
*** IBB - CNR ***
Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia.
Medical Laboratory Technology Department, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia.
Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
King Fahd Medical Research Center, and Yousef Abdullatif Jameel Chair of Prophetic Medicine Application, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
School of Life Sciences, Manipal Academy of Higher Education, Dubai, United Arab Emirates.
Institute of Biostructure and Bioimaging (CNR), Molecular Biotechnology Center, Turin, Italy.
Unit of Gastroenterology, Molinette Hospital, Turin, Italy.
References:
Not available.
Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients
Metastatic melanoma has less frequency, but considered as the most dreaded cancer. The combination of nivolumab & ipilimumab is proving their mettle in treating metastatic melanoma. The patients when administered with the combination of nivolumab & ipilimumab have shown improved median progression free survival, objective response rate and overall survival rate compared with nivolumab and ipilimumab monotherapy. The combination shrinks the tumor cells by attacking different checkpoints viz. CTLA-4 and PD-L1, respectively. The combination treatment reveals reduced disease progression and suggests nivolumab's non-cross resistant nature. The median progression free survival in "nivolumab plus ipilimumab" group has shown an increase of 66.7% and 296.6% in comparison to nivolumab and ipilimumab monotherapy. The other parameter viz. objective response rate improvement is equivalent to almost 14% and 38.6% when compared to nivolumab and ipilimumab monotherapy, respectively.
Metastatic melanoma has less frequency, but considered as the most dreaded cancer. The combination of nivolumab & ipilimumab is proving their mettle in treating metastatic melanoma. The patients when administered with the combination of nivolumab & ipilimumab have shown improved median progression free survival, objective response rate and overall survival rate compared with nivolumab and ipilimumab monotherapy. The combination shrinks the tumor cells by attacking different checkpoints viz. CTLA-4 and PD-L1, respectively. The combination treatment reveals reduced disease progression and suggests nivolumab's non-cross resistant nature. The median progression free survival in "nivolumab plus ipilimumab" group has shown an increase of 66.7% and 296.6% in comparison to nivolumab and ipilimumab monotherapy. The other parameter viz. objective response rate improvement is equivalent to almost 14% and 38.6% when compared to nivolumab and ipilimumab monotherapy, respectively.
Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients
No results. |
156 views. Last view on Monday 07 October 2024, 4:26:17
ibb.cnr.it
